A drug which helps extend the life of women with advanced breast cancer has been rejected for use in the public health system.
According to a report in the Sunday Business Post, the National Centre for Pharmaco-economics concluded the drug did not represent value for money.
Kadcyla is designed for women with inoperable cancer which has spread to other parts of the body, and costs €80,000 per course.
It is not a cure, but can extend life by up to six months.
